马睿, 刘飞艳, 苏峰, 董新军. VEGF在恶性胸腔积液中的作用[J]. 中国辐射卫生, 2017, 26(4): 507-510.
MA Rui, LIU Fei-yan, SU Feng, DONG Xinjun. The Role of VEGF in Malignant Pleural Effusion. , 2017, 26(4): 507-510.
[1] Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions[J]. Mayo Clin Proc, 2008,83(2):235-250. [2] Morgensztern D, Waqar S, Subramanian J, et al. Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer[J].J Thorac Oncol,2012,7(10):1485-1489. [3] Bates DO. Vascular endothelial growth factors and vascular permeability[J]. Cardiovasc Res, 2010,87(2):262-271. [4] Satchell SC, Braet F. Glomerular endothelial cell fenestrations:an integral component of the glomerular filtration barrier[J]. Am J Physiol Renal Physiol, 2009,296(5):947-956. [5] Fiorelli A, Vicidomini G, Di Domenico M, et al. Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications[J]. Interact Cardiovasc Thorac Surg,2011,12(3):420-424. [6] Lieser E, Bradshaw M, Croghan G, et al. Proangiogenesis factors and cell phenotyping in the etiology and diagnosis of malignant pleural effusions[J]. J Thorac Oncol, 2011,6(6):750-751. [7] Cui R, Takahashi F, Ohashi R, et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer[J]. Lung Cancer, 2009,63(3):368-374. [8] Stathopoulos GT, Sherrill TP, Karabela SP, et al. Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion[J]. Am J Respir Crit Care Med, 2010,182(10):1273-1281. [9] Stathopoulos GT, Kalomenidis I. Malignant pleural effusion:tumor-host interactions unleashed[J]. Am J Respir Crit Care Med,2012,186(6):487-92. [10] Korpanty G, Smyth E, Sullivan LA, et al. Antiangiogenic therapy in lung cancer:focus on vascular endothelial growth factor pathway[J]. Exp Biol Med (Maywood),2010,235(1):3-9. [11] Mitchell EP. Targeted therapy for metastatic colorectal cancer:role of aflibercept[J]. Clin Colorectal Cancer, 2012. [12] Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab[J]. Oncologist, 2010,15(8):819-25. doi:10.1634/theoncologist.2009-0317. [13] Edge SB. American Joint Committee on Cancer. AJCC cancer staging manual[M]. 7th ed, New York:Springer, 2010. [14] Abouzgheib W, Bartter T, Dagher H, et al. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion[J]. Chest,2009,135(4):999-1001. [15] Matveychuk A, Rashid G, Fridman Z, et al. Pleural ELFA D-dimer assay:a surrogate marker for malignant pleural effusion[J]. Thromb Res, 2012,129(5):648-651. [16] Pernemalm M, De Petris L, Eriksson H, et al. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion[J]. Proteomics, 2009,9(13):3414-3424. [17] Rodriguez-Pineiro AM, Blanco-Prieto S, Sanchez-Otero N, et al. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion[J]. J Proteomics, 2010,73(8):1511-1522. [18] Botana-Rial M, Casado-Rey P, Leiro-Fernandez V, et al. Validity of procalcitonin and C-reactive protein measurement when differentiating between benign and malignant pleural effusion[J]. Clin Lab,2011,57(5-6):373-378. [19] Yu CJ, Wang CL, Wang CI, et al.Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology[J]. J Proteome Res,2011,10(10):4671-4682. [20] Shen YC, Liu MQ, Wan C, et al. Diagnostic accuracy of vascular endothelial growth factor for malignant pleural effusion:a meta-analysis[J]. Exp Ther Med, 2012,3(6):1072-1076. [21] Hirayama N, Tabata C, Tabata R, et al. Pleural effusion VEGF levels as a prognostic factor of malignant pleural mesothelioma[J]. Respir Med, 2011,105(1):137-142. [22] Demmy TL, Gu L, Burkhalter JE, et al. Optimal management of malignant pleural effusions (results of CALGB 30102)[J]. J Natl Compr Canc Netw,2012,10(8):975-982. [23] Olden AM, Holloway R. Treatment of malignant pleural effusion:PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis[J]. J Palliat Med, 2010,13(1):59-65. [24] Suzuki K, Servais EL, Rizk NP, et al. Palliation and pleurodesis in malignant pleural effusion:the role for tunneled pleural catheters[J].J Thorac Oncol, 2011, 6(4):762-767. [25] Van Meter ME, McKee KY, Kohlwes RJ. Efficacy and safety of tunneled pleural catheters in adults with malignant pleural effusions:a systematic review[J].J Gen Intern Med, 2011,26(1):70-76. [26] Jones DR, Taylor MD, Petroni GR, et al. Phase I trial of intrapleural docetaxel administered through an implantable catheter in subjects with a malignant pleural effusion[J].J Thorac Oncol,2010,5(1):75-81. [27] Sterman DH, Recio A, Haas AR, et al. A phase I trial of repeated intrapleural adenoviralmediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions[J]. Mol Ther, 2010,18(4):852-860. [28] Ribeiro SC, Vargas FS, Antonangelo L, et al. Monoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusion[J]. Respirology, 2009,14(8):1188-1193. [29] Teixeira LR, Vargas FS, Acencio MM, et al. Blockage of vascular endothelial growth factor (VEGF) reduces experimental pleurodesis[J]. Lung Cancer,2011. [30] Kitamura K, Kubota K, Ando M, et al. Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion[J]. Cancer Chemother Pharmacol, 2013,71(2):457-461.